2017;70:1785C822. CouncilSt. Lukes University or college Health NetworkCCardiac Nurse PractitionerDeborah J. WexlerContent Reviewer-ACC ExpertHarvard Medical SchoolCAssociate Professor of Medicine; Massachusetts General HospitalCAssociate Clinical Chief, Diabetes UnitNathan D. WongContent Reviewer-Prevention Council and Roundtable ParticipantUniversity of California, IrvineCProfessor and Director, UCI Heart Disease Prevention Program Open in a separate window AACE = American Association of Clinical Endocrinology; AAFP = American Academy of Family Physicians; AANP = American Association of Nurse Practitioners; ABC = Association of Black Cardiologists; ACC = American College of Cardiology; ADA = American Diabetes Association; AHA = American Heart Association; APA = American Pharmacists Association; ASHP = American Society of Health-System Pharmacists; ASPC = American Society for Preventive Cardiology; BOG = Board of Governors; CVD = cardiovascular disease; NLA = National Lipid Association; PCNA = Preventive Cardiovascular Nurses Association; VA = Veterans Administration. APPENDIX 3.?ABBREVIATIONS A1C = hemoglobin A1CGLP-1RA = Mycophenolate mofetil (CellCept) glucagon-like peptide-1 Mycophenolate mofetil (CellCept) receptor agonistACC = American College of CardiologyHFSA = Heart Failure Society of AmericaADA = American Diabetes AssociationMACE = major adverse cardiovascular eventAHA Mycophenolate mofetil (CellCept) = American Heart AssociationMI = myocardial infarctionASCVD = atherosclerotic cardiovascular diseaseSGLT2 = sodium-glucose cotransporter-2CV = cardiovascularT2D = type 2 diabetes mellituseGFR = estimated glomerular filtration rate Open in a separate window Footnotes Endorsed by the American Diabetes Assocation This document was approved by the American College of Cardiology Clinical Policy Approval Committee in October 2018. The American College of Cardiology requests that Mycophenolate mofetil (CellCept) this document be cited as follows: Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, Sperling LS. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018;72:3200-23. REFERENCES 1. American Diabetes Association. Statistics About Diabetes: American Diabetes Association; Available at: http://www.diabetes.org/diabetes-basics/statistics/. Accessed January 29, 2018. [Google Scholar] 2. Rawshani A, Rawshani A, Gudbjornsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;377:300C1. [PubMed] [Google Scholar] 3. Professional Practice Committee. Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S3. [PubMed] [Google Scholar] 4. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48:643C8. [PMC free article] [PubMed] [Google Scholar] 5. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122:844C6. [PMC free article] [PubMed] [Google Scholar] 6. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560C72. [PubMed] [Google Scholar] 7. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type CD247 2 diabetes. N Engl J Med. 2009;360:129C39. [PubMed] [Google Scholar] 8. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S86C104. [PubMed] [Google Scholar] 9. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323C34. [PubMed] [Google Scholar] 10. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311C22. [PMC free article] [PubMed] [Google Scholar] 11. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834C44. [PubMed] [Google Scholar] 12. Neal B, Perkovic V, Mahaffey KW,.